Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform

Jingen Zhu, Pan Tao, Ashok K. Chopra, Venigalla B. Rao

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

The COVID-19 pandemic has transformed vaccinology. Rapid deployment of mRNA vaccines has saved countless lives. However, these platforms have inherent limitations including lack of durability of immune responses and mucosal immunity, high cost, and thermal instability. These and uncertainties about the nature of future pandemics underscore the need for exploring next-generation vaccine platforms. Here, we present a novel protein-based, bacteriophage T4 platform for rapid design of efficacious vaccines against bacterial and viral pathogens. Full-length antigens can be displayed at high density on a 120 × 86 nm phage capsid through nonessential capsid binding proteins Soc and Hoc. Such nanoparticles, without any adjuvant, induce robust humoral, cellular, and mucosal responses when administered intranasally and confer sterilizing immunity. Combined with structural stability and ease of manufacture, T4 phage provides an excellent needle-free, mucosal pandemic vaccine platform and allows equitable vaccine access to low- and middle-income communities across the globe.

Original languageEnglish (US)
Pages (from-to)395-420
Number of pages26
JournalAnnual Review of Virology
Volume11
Issue number1
DOIs
StatePublished - Sep 26 2024
Externally publishedYes

Keywords

  • CRISPR engineering
  • bacteriophage T4 assembly
  • broad humoral immunity
  • cellular immunity
  • mucosal immunity
  • needle- and adjuvant-free intranasal vaccines
  • pandemic vaccine design

ASJC Scopus subject areas

  • Virology

Fingerprint

Dive into the research topics of 'Bacteriophage T4 as a Protein-Based, Adjuvant- and Needle-Free, Mucosal Pandemic Vaccine Design Platform'. Together they form a unique fingerprint.

Cite this